Navigation Links
K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission
Date:12/27/2010

have an adverse effect on us if we are not able to refinance it or repay it at maturity on March 20, 2013, or earlier if we experience an event of default and such terms contain numerous affirmative and negative covenants and conditions that must be met in order to avoid default and/or to qualify for additional loan tranches, and there are substantial risks of triggering defaults with respect to such covenants and/or the occurrence or non-occurrence of conditions that would preclude the Company from being able to draw down additional loan tranches, which could materially adversely impact the Company, lead to foreclosure on the Company assets acting as collateral for the loan agreement, and adversely affect the Company's ability to operate;

(3)  the possibility of not obtaining FDA approvals or delay in obtaining FDA approvals, including with respect to the drug originally submitted under the trade name Gestiva™ ("Gestiva™")

(4)  new product development and launch, including the possibility that any product launch may be delayed or unsuccessful, including with respect to Gestiva™;

(5)  acceptance of and demand for the Company's new pharmaceutical products, including Gestiva™, and for our current products upon their return to the marketplace, as well as the number of preterm births for which Gestiva™ may be prescribed and its safety profile and side effects profile;

(6)  the possibility that any period of exclusivity may not be realized, including with respect to Gestiva™, a designated Orphan Drug;

(7)  the satisfaction or waiver of the terms and conditions for the acquisition of the full U.S. and worldwide rights to Gestiva™ set forth in the previously disclosed Gestiva™ acquisition agreement, as amended;

(8)  the consent decree between the Company and the U.S. Food and Drug Administration ("FDA") and the Company's suspension of the production and
'/>"/>

SOURCE K-V Pharmaceutical Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that ... 31, 2014 on March 9, 2015. The Company also plans to ... 12, 2015, at 5:00 pm ET. The call will be hosted ...   , , , LIVE CALL:  , , , ... , , , , , ...
(Date:3/1/2015)... , March 1, 2015  An innovative ... chronic migraine sufferers sustained relief of their headaches, ... Society of Interventional Radiology ,s Annual Scientific ... the State University New York Empire State College ... intranasal sphenopalatine ganglion (SPG) blocks to give patients ...
(Date:2/27/2015)... Feb. 27, 2015 Pharmaceutical and biotech marketers ... products for the same indication. This can be a ... to prevent one of their brands from gaining market ... to recent research by benchmarking firm, Best Practices, LLC, ... brands rather than together as part of a franchise. ...
Breaking Medicine Technology:ImmunoCellular Therapeutics to Report 2014 Financial Results on March 9, 2015; a Business Update Conference Call and Webcast is Scheduled for March 12, 2015 2Image-guided treatment shown to break the migraine cycle 2Image-guided treatment shown to break the migraine cycle 3Image-guided treatment shown to break the migraine cycle 4New Report Details How to Expand a Pharmaceutical Product Portfolio without Cannibalizing an Established Brand 2
... Scientific Corporation (NYSE: BSX ) today announced ... 60th Annual Scientific Session of the American College of ... "Twelve-month results from the PLATINUM Workhorse clinical trial ... Everolimus-Eluting Platinum Chromium (PtCr) Stent as compared to our ...
... DIEGO, March 29, 2011 Awarepoint Corporation announced ... at the First Annual Digital Healthcare Innovation Summit ... Intercontinental New York Barclay in New York. Joining Deady on ... of Dell Healthcare Services and Kaveh Safavi, M.D., vice president ...
Cached Medicine Technology:Boston Scientific Announces Its ACC 2011 Schedule 2Boston Scientific Announces Its ACC 2011 Schedule 3Boston Scientific Announces Its ACC 2011 Schedule 4Boston Scientific Announces Its ACC 2011 Schedule 5Boston Scientific Announces Its ACC 2011 Schedule 6Awarepoint CEO Jay Deady to Serve as Panelist at IBF's Digital Healthcare Innovation Summit 2Awarepoint CEO Jay Deady to Serve as Panelist at IBF's Digital Healthcare Innovation Summit 3
(Date:3/2/2015)... March 02, 2015 Four Seasons Resort Maui ... its 25th anniversary this year, having officially opened its doors ... luxury resort is honoring over 70 employees who started on ... from amongst the approximately 400 original employees. The celebration ... Oceanfront Lawn. , This Four Seasons flagship resort, ...
(Date:3/2/2015)... 02, 2015 In light of the ... Xarelto (rivaroxaban) tablets, Ford & Associates Nationwide ... helpful for future users, but may come too late ... taking the drug. The FDA has now included the ... Reactions on Xarelto's label. The term “cytolytic hepatitis” has ...
(Date:3/2/2015)... March 02, 2015 Many mainstream media ... cases of measles. But how much of that news ... their toddlers to prevent measles, but whose youngsters later ... lectures from 150 speakers comprised of professionals, clinicians, researchers, ... recent news stories and questions about the body and ...
(Date:3/2/2015)... California (PRWEB) March 02, 2015 Final ... of the TranStatic Volume 2 from Pixel Film Studios. , ... made exclusively for FCPX,” said Christina Austin, CEO of Pixel ... have in any Final Cut Pro X editors toolbox.” , ... to the next with media altering static scrambling effects from ...
(Date:3/1/2015)... 2015 Security Life Insurance Company ... market, announced the addition of stand-alone individual vision ... Insurance launched today, complete with two plan options. ... the VSP® Vision Care network encompassing a strong ... space. The PrimeStar Select Vision plan will use ...
Breaking Medicine News(10 mins):Health News:Celebrating Four Seasons Resort Maui’s 25th Anniversary 2Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 2Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 3Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 4Health News:Growing List of Professionals Gather for World’s Most Comprehensive Autism Conference in Chicago, May 2015 2Health News:Pixel Film Studios released the TranStatic Volume 2 plugin for Final Cut Pro X today 2Health News:Security Life Insurance Company Launches Individual Vision Insurance Product 2
... PAUL, Minn., Jan. 29 U.S. President Barack ... on human embryonic stem cells (hESC) research and is ... the issue. On Aug. 9, 2001, the Bush administration ... those hESC lines derived before that date. Jonathan ...
... have complications, without ill effects, study finds , , THURSDAY, Jan. ... to babies still in the womb can reduce their post-birth ... growth the way multiple courses can, new research shows. , ... those given a second dose of steroids in utero had ...
... PRO Educational Initiative are AnnouncedPITTSBURGH, Jan. 29 ... electronic patient reported outcomes (ePRO) solutions and ... opened registration for ePROficiency(TM) 2009 -- its ... research professionals can visit http://www.invivodata.com/epro2009 ...
... American businesses take belt-,tightening to new levels to ... a new service to help organizations address one ... EquivaMeds ( www.EquivaMeds.com ) helps self-insured ... helps members analyze their,current medications, identify lower cost ...
... interventions developed by UCSF researchers have been selected ... and Prevention,s 2008 Compendium of Evidence-based HIV Prevention ... Video Doctor and the Healthy Living Projectcomprise two ... 57 rigorously evaluated highly effective HIV prevention programs ...
... BTA stat(R) Test Detects Bladder Tumor Associated Antigen in UrineCORTLANDT ... announce the direct availability of the BTA stat (R) ... (R) test is a point of care technology for the ... antibodies to detect the presence of bladder tumor associated antigen ...
Cached Medicine News:Health News:University of Minnesota's Internationally Recognized Stem Cell Experts Available for Interviews on What Lifting the Federal Funding Restrictions Will Mean to Stem Cell Research and to Patients Who Stand to Benefit 2Health News:Additional Steroid Dose May Help Preemies 2Health News:Additional Steroid Dose May Help Preemies 3Health News:invivodata Opens Registration for Annual Patient Reported Outcomes Conference 2Health News:invivodata Opens Registration for Annual Patient Reported Outcomes Conference 3Health News:CDC recognizes UCSF's research as critical to HIV prevention 2Health News:CDC recognizes UCSF's research as critical to HIV prevention 3Health News:Polymedco Introduces Point of Care Test for Recurrent Bladder Cancer Detection 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: